<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="449FF167-3231-98AA-C60C-673E026CF86A" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">TERRAMYCIN<sup>&#174;</sup><br />oxytetracycline<br />hydrochloride<br />CAPSULES</title>
<effectiveTime value="20051207" />
<availabilityTime />
<confidentialityCode code="N" codeSystem="2.16.840.1.113883.5.25" codeSystemName="Confidentiality" />
<setId root="6B4DE8C9-8A32-4A07-9183-419D6177EA08" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Pfizer Labs</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="B6DD4416-93F0-391C-6345-D0C157BDC767" />
<effectiveTime value="20051207" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0069-0730" codeSystem="2.16.840.1.113883.6.69" codeSystemName="FDA" displayName="NDC" />
<name>Terramycin</name>
<formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="250">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="250" />
</numerator>
<denominator value="1">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="4U7K4N52ZM" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Oxytetracycline Hydrochloride</name>
<activeMoiety>
<activeMoiety>
<code code="X20I9EN955" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Oxytetracycline</name>
</activeMoiety>
</activeMoiety>
<activeMoiety>
<activeMoiety>
<code code="X20I9EN955" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Oxytetracycline</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Oxytetracycline Hydrochloride</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>glucosamine hydrochloride</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>hard gelatin capsules</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Red 3</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Yellow 10</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium lauryl sulfate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0069-0730-66" codeSystem="2.16.840.1.113883.6.69" codeSystemName="FDA" displayName="NDC" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="500">
<translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" value="500" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0069-0730-73" codeSystem="2.16.840.1.113883.6.69" codeSystemName="FDA" displayName="NDC" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"><originalText>Opaque Yellow</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"><originalText>Capsule</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="22" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Terramycin;Pfizer;073</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="3CD7544F-E973-E025-15A5-642BD4CCC127" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>Oxytetracycline is a product of the metabolism of <content styleCode="italics">Streptomyces rimosus</content> and is one of the family of tetracycline antibiotics. A 1 percent solution in water is acidic (pH about 2.5). Its potency is affected in solutions more acid than pH 2 and it is rapidly destroyed by alkali hydroxides.</paragraph><paragraph>Oxytetracycline diffuses readily through the placenta into the fetal circulation, into the pleural fluid and, under some circumstances, into the cerebrospinal fluid. It appears to be concentrated in the hepatic system and excreted in the bile, so that it appears in the feces, as well as in the urine, in a biologically active form.</paragraph><paragraph>Inert ingredients in the formulation are: glucosamine hydrochloride; hard gelatin capsules (which may contain Red 3, Yellow 10 and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="F7D0D40C-8500-4B57-357C-20ED562D39DB" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">ACTIONS</title>
<text><paragraph>Oxytetracycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Oxytetracycline is active against a wide range of gram-negative and gram-positive organisms.</paragraph><paragraph>The drugs in the tetracycline class have closely similar antimicrobial spectra, and cross resistance among them is common. Microorganisms may be considered susceptible if the M.I.C. (minimum inhibitory concentration) is not more than 4.0 mcg/ml and intermediate if the M.I.C. is 4.0 to 12.5 mcg/ml.</paragraph><paragraph>Susceptibility plate testing: A tetracycline disc may be used to determine microbial susceptibility to drugs in the tetracycline class. If the Kirby-Bauer method of disc susceptibility testing is used, a 30 mcg tetracycline disc should give a zone of at least 19 mm when tested against a tetracycline-susceptible bacterial strain.</paragraph><paragraph>Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="82684953-FE10-ED5E-5DD2-A7E8A89FD1D4" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS</title>
<text><paragraph>Oxytetracycline is indicated in infections caused by the following microorganisms:</paragraph><list listType="unordered"><item>Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers),</item><item><content styleCode="italics">Mycoplasma pneumoniae</content> (PPLO, Eaton Agent),</item><item>Agents of psittacosis and ornithosis,</item><item>Agents of lymphogranuloma venereum and granuloma inguinale,</item><item>The spirochetal agent of relapsing fever (<content styleCode="italics">Borrelia recurrentis</content>).</item></list><paragraph>The following gram negative microorganisms:</paragraph><list listType="unordered"><item><content styleCode="italics">Haemophilus ducreyi</content> (chancroid),</item><item><content styleCode="italics">Pasteurella pestis</content>, and <content styleCode="italics">Pasteurella tularensis</content>,</item><item><content styleCode="italics">Bartonella bacilliformis</content>,</item><item><content styleCode="italics">Bacteroides</content> species,</item><item><content styleCode="italics">Vibrio comma</content> and <content styleCode="italics">Vibrio fetus</content>,</item><item><content styleCode="italics">Brucella</content> species (in conjunction with streptomycin).</item></list><paragraph>Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended.</paragraph><paragraph>Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:</paragraph><list listType="unordered"><item><content styleCode="italics">Escherichia coli</content>,</item><item><content styleCode="italics">Enterobacter aerogenes</content> (formerly <content styleCode="italics">Aerobacter aerogenes</content>),</item><item><content styleCode="italics">Shigella</content> species,</item><item><content styleCode="italics">Mima</content> species and <content styleCode="italics">Herellea</content> species,</item><item><content styleCode="italics">Haemophilus influenzae</content> (respiratory infections),</item><item><content styleCode="italics">Klebsiella</content> species (respiratory and urinary infections).</item></list><paragraph>Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:</paragraph><paragraph><content styleCode="italics">Streptococcus</content> species:</paragraph><paragraph>Up to 44 percent of strains of <content styleCode="italics">Streptococcus pyogenes</content> and 74 percent of <content styleCode="italics">Streptococcus faecalis</content> have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive.</paragraph><paragraph>For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever.</paragraph><paragraph><content styleCode="italics">Diplococcus pneumoniae</content>,</paragraph><paragraph><content styleCode="italics">Staphylococcus aureus</content>, skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections.</paragraph><paragraph>When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to:</paragraph><list listType="unordered"><item><content styleCode="italics">Neisseria gonorrhoeae</content>,</item><item><content styleCode="italics">Treponema pallidum</content> and <content styleCode="italics">Treponema pertenue</content> (syphilis and yaws),</item><item><content styleCode="italics">Listeria monocytogenes</content>,</item><item><content styleCode="italics">Clostridium</content> species,</item><item><content styleCode="italics">Bacillus anthracis</content>,</item><item><content styleCode="italics">Fusobacterium fusiforme</content> (Vincent's infection),</item><item><content styleCode="italics">Actinomyces</content> species.</item></list><paragraph>In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides.</paragraph><paragraph>In severe acne, the tetracyclines may be useful adjunctive therapy.</paragraph><paragraph>Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence.</paragraph><paragraph>Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="AD28D58B-25F1-E6DB-B47E-EF7355E24826" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section ID="Warnings">
<id root="D1A3EC64-9F4D-DAC7-7067-501470B56E3F" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long term use of the drugs but has been observed following repeated short term courses. Enamel hypoplasia has also been reported. <content styleCode="italics">TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED</content>.</paragraph><paragraph>If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated and, if therapy is prolonged, serum level determinations of the drug may be advisable.</paragraph><paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.</paragraph><paragraph>The antianabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia, and acidosis.</paragraph><paragraph><content styleCode="italics">Usage in pregnancy:</content> (See above <linkHtml href="#Warnings">WARNINGS</linkHtml> about use during tooth development.)</paragraph><paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy.</paragraph><paragraph><content styleCode="italics">Usage in newborns, infants, and children</content>. (See above<linkHtml href="#Warnings"> WARNINGS</linkHtml> about use during tooth development.)</paragraph><paragraph>All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.</paragraph><paragraph>Tetracyclines are present in the milk of lactating women who are taking a drug in this class.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="8C954615-86C3-3C04-0AA5-B57711204D15" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text><paragraph>As with other antibiotic preparations, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.</paragraph><paragraph>In venereal diseases when coexistent syphilis is suspected, a dark field examination should be done before treatment is started and the blood serology repeated monthly for at least 4 months.</paragraph><paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph><paragraph>In long term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed.</paragraph><paragraph>All infections due to Group A beta-hemolytic streptococci should be treated for at least 10 days.</paragraph><paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline in conjunction with penicillin.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section ID="Adverse_Reactions">
<id root="73F05D1E-C7B8-C799-53E3-C9BF6B7BA1A3" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See <linkHtml href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</linkHtml>.)</paragraph><paragraph>Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph><paragraph>Renal toxicity: Rise in BUN has been reported and is apparently dose related. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph><paragraph>Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, pericarditis and exacerbation of systemic lupus erythematosus.</paragraph><paragraph>Bulging fontanels in infants and benign intracranial hypertension in adults have been reported in individuals receiving full therapeutic dosages. These conditions disappeared rapidly when the drug was discontinued.</paragraph><paragraph>Blood: Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported.</paragraph><paragraph>When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function studies are known to occur.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section ID="Dosage_And_Administration">
<id root="208ED4C5-94DE-7683-6B44-13596225BF57" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>Adults: Usual daily dose, 1&#8211;2 g divided in four equal doses, depending on the severity of the infection.</paragraph><paragraph>For children above eight years of age: Usual daily dose, 10&#8211;20 mg per pound (25&#8211;50 mg/kg) of body weight divided in four equal doses.</paragraph><paragraph>Therapy should be continued for at least 24&#8211;48 hours after symptoms and fever have subsided.</paragraph><paragraph>For treatment of brucellosis, 500 mg oxytetracycline four times daily for 3 weeks should be accompanied by streptomycin, 1 gram intramuscularly twice daily the first week, and once daily the second week.</paragraph><paragraph>For treatment of uncomplicated gonorrhea, when penicillin is contraindicated, tetracycline may be used for the treatment of both males and females in the following divided dosage schedule: 1.5 grams initially followed by 0.5 gram q.i.d. for a total of 9.0 grams.</paragraph><paragraph>For treatment of syphilis, a total of 30&#8211;40 grams in equally divided doses over a period of 10&#8211;15 days should be given. Close follow-up, including laboratory tests, is recommended.</paragraph><paragraph>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See <linkHtml href="#Adverse_Reactions">ADVERSE REACTIONS</linkHtml>.)</paragraph><paragraph>Concomitant therapy: Antacids containing aluminum, calcium, or magnesium impair absorption and should not be given to patients taking oral tetracyclines.</paragraph><paragraph>Food and some dairy products also interfere with absorption. Oral forms of tetracyclines should be given 1 hour before or 2 hours after meals. Pediatric oral dosage forms should not be given with milk formulas and should be given at least 1 hour prior to feeding.</paragraph><paragraph>In patients with renal impairment (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.) Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses.</paragraph><paragraph>In the treatment of streptococcal infections, a therapeutic dose of oxytetracycline should be administered for at least 10 days.</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="BE0B64EF-2F83-347F-74D6-0F9D990ACAC1" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>Terramycin (oxytetracycline HCl) Capsules are available as opaque, yellow, hard gelatin capsules which contain oxytetracycline HCl equivalent to 250 mg of oxytetracycline, and glucosamine hydrochloride: bottles of 100 (NDC 0069-0730-66), 500 (NDC 0069-0730-73).</paragraph></text>
<effectiveTime value="20051207" />
</section>
</component>
<component>
<section>
<id root="67E5680B-45C5-AF68-C30D-CE0C2FFD82AB" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph><content styleCode="bold">Rx only</content></paragraph><renderMultiMedia referencedObject="MM1" /><paragraph>69-0755-32-7</paragraph><paragraph>March 1987</paragraph></text>
<effectiveTime value="20051207" />
<component>
<observationMedia ID="MM1">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="terramycin-caps-image01.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
